GenSight Biologics S.A. (GSGTF)
USD 0.24
(0.0%)
USD 0.24
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 16.29 Million EUR | 647.4% |
| 2022 | 2.18 Million USD | 106.05% |
| 2021 | -36.05 Million USD | -25.44% |
| 2020 | -28.74 Million USD | -112.48% |
| 2019 | -13.52 Million USD | 49.06% |
| 2018 | -26.55 Million EUR | 58.21% |
| 2017 | -63.54 Million EUR | -17.65% |
| 2016 | -54.01 Million EUR | -68.63% |
| 2015 | -32.03 Million EUR | -219.13% |
| 2014 | -10.03 Million EUR | 41.28% |
| 2013 | -17.09 Million EUR | -90600.36% |
| 2012 | -18.84 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q1 | 19.81 Million EUR | 872.71% |
| 2023 Q3 | 20.62 Million EUR | 25.91% |
| 2023 FY | 16.29 Million EUR | 647.4% |
| 2023 Q4 | 16.29 Million EUR | -21.0% |
| 2023 Q2 | 16.38 Million USD | -17.32% |
| 2022 Q3 | 6.35 Million EUR | 146.2% |
| 2022 FY | 2.18 Million USD | 106.05% |
| 2022 Q1 | -8.94 Million EUR | 71.81% |
| 2022 Q2 | -13.76 Million EUR | -53.85% |
| 2022 Q4 | 2.03 Million EUR | -67.96% |
| 2021 Q3 | -27.51 Million EUR | 31.6% |
| 2021 Q4 | -31.72 Million EUR | -15.28% |
| 2021 Q2 | -40.23 Million EUR | -11.71% |
| 2021 FY | -36.05 Million USD | -25.44% |
| 2021 Q1 | -36.01 Million EUR | -53.3% |
| 2020 FY | -28.74 Million USD | -112.48% |
| 2020 Q4 | -23.49 Million EUR | -21.26% |
| 2020 Q3 | -19.37 Million EUR | -327.12% |
| 2020 Q2 | -4.53 Million EUR | -227.27% |
| 2020 Q1 | -1.38 Million EUR | 88.5% |
| 2019 Q4 | -12.05 Million EUR | -34.18% |
| 2019 Q1 | -7.37 Million EUR | 67.68% |
| 2019 Q2 | -10.17 Million EUR | -38.02% |
| 2019 Q3 | -8.98 Million EUR | 11.7% |
| 2019 FY | -13.52 Million USD | 49.06% |
| 2018 Q1 | -38.26 Million EUR | 26.99% |
| 2018 Q4 | -22.8 Million EUR | 0.0% |
| 2018 FY | -26.55 Million EUR | 58.21% |
| 2018 Q3 | -22.8 Million EUR | 40.42% |
| 2018 Q2 | -38.26 Million EUR | 0.0% |
| 2017 Q3 | -52.41 Million EUR | 13.96% |
| 2017 Q2 | -60.91 Million EUR | 0.0% |
| 2017 Q1 | -60.91 Million EUR | -19.3% |
| 2017 FY | -63.54 Million EUR | -17.65% |
| 2017 Q4 | -52.41 Million EUR | 0.0% |
| 2016 Q3 | -51.06 Million EUR | 0.0% |
| 2016 Q4 | -51.06 Million EUR | 0.0% |
| 2016 Q1 | 30.05 Million EUR | 202.11% |
| 2016 FY | -54.01 Million EUR | -68.63% |
| 2015 FY | -32.03 Million EUR | -219.13% |
| 2015 Q3 | -29.43 Million EUR | -448.83% |
| 2015 Q4 | -29.43 Million EUR | 0.0% |
| 2015 Q2 | -5.36 Million EUR | 0.0% |
| 2015 Q1 | -5.36 Million EUR | 46.56% |
| 2014 Q4 | -10.03 Million EUR | 0.0% |
| 2014 Q1 | 17.09 Million EUR | 0.0% |
| 2014 FY | -10.03 Million EUR | 41.28% |
| 2014 Q3 | -10.03 Million EUR | 0.0% |
| 2013 FY | -17.09 Million EUR | -90600.36% |
| 2012 FY | -18.84 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 2520.779% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -1242.298% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -1516.924% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 61.924% |
| GB Sciences, Inc. | 1.74 Million USD | -832.516% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 284.323% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 175902.787% |
| Skye Bioscience, Inc. | -5.72 Million USD | 384.791% |
| Zenith Capital Corp. | 10.06 Thousand USD | -161803.816% |
| Agentix Corp. | 37.63 Thousand USD | -43199.407% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -188.473% |
| Biomind Labs Inc. | 711.4 Thousand USD | -2190.407% |
| ContraFect Corporation | -6.02 Million USD | 370.395% |
| CSL Limited | 10.52 Billion USD | 99.845% |
| CytoDyn Inc. | 20.26 Million USD | 19.583% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -4429.76% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -2518.082% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 62.486% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 79941.239% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -1657.36% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -2465.31% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 358.449% |
| SQZ Biotechnologies Company | -36.23 Million USD | 144.964% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -1794.12% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -3.369% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -626.686% |
| Mesoblast Limited | 55.85 Million USD | 70.83% |
| Marizyme, Inc. | 18.56 Million USD | 12.252% |
| Genus plc | 190.6 Million USD | 91.451% |
| Pharming Group N.V. | 109.8 Million USD | 85.161% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -2296.176% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -1310.212% |
| IMV Inc. | 7.67 Million USD | -112.424% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -196.152% |
| MultiCell Technologies, Inc. | 90.04 USD | -18096301.599% |
| ONE Bio Corp. | 9.04 Million USD | -80.243% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -25.861% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 46.671% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -714.948% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -27.231% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -11554.888% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -81915.402% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 8965.65% |
| Enzolytics Inc. | 981.65 Thousand USD | -1559.848% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.803% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 134.659% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -130.435% |
| Genscript Biotech Corporation | -1.06 Billion USD | 101.535% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -295.675% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -3954.757% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -582.891% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -9804.625% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 89050.759% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -628.767% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -12001.991% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 2319.958% |
| Helix BioMedix, Inc. | -2.57 Million USD | 734.0% |
| EV Biologics, Inc. | 1.36 Million USD | -1091.107% |
| Q BioMed Inc. | 4.06 Million USD | -301.329% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 19.639% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 73.088% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | -264.355% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -639.97% |
| HST Global, Inc. | 96.79 Thousand USD | -16733.862% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 1243916.794% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -7801.385% |
| Halberd Corporation | 144.72 Thousand USD | -11158.905% |
| Resverlogix Corp. | 6.45 Million USD | -152.581% |
| Cell Source, Inc. | 9.23 Million USD | -76.495% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -501.562% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | -5.9 Million USD | 376.019% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -8029.44% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | -647.958% |
| Kadimastem Ltd | -253.1 Thousand USD | 6537.721% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -11881.851% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -7996.237% |
| LadRx Corporation | -2.03 Million USD | 900.11% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -2465.31% |
| Affymax, Inc. | -5.59 Million USD | 391.12% |
| Itoco Inc. | 228.3 Thousand USD | -7036.944% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -228.707% |
| Mobile Lads Corp. | 484.23 Thousand USD | -3264.916% |
| International Stem Cell Corporation | 2.59 Million USD | -529.112% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 1.89 Million USD | -758.069% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 2518492.581% |
| Qrons Inc. | 351.42 Thousand USD | -4536.525% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -111.446% |
| SYBLEU INC | 473.71 Thousand USD | -3339.628% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 6627.522% |
| Rebus Holdings, Inc. | 305 Thousand USD | -5242.295% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -265.58% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -26006.741% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -647.123% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -374.49% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -90.506% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -2008.964% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 1403.52% |
| Neutra Corp. | 52.18 Thousand USD | -31122.335% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 754.64% |
| PureTech Health plc | -167.19 Million USD | 109.745% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 6753.111% |
| IXICO plc | -4.44 Million USD | 466.603% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -23.262% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 70.294% |
| CSL Limited | 10.52 Billion USD | 99.845% |
| Cellectis S.A. | -43.81 Million USD | 137.185% |